Atorvastin

The IDEAL trial is the rare statin study that actually published its harm numbers, and they are worse than the benefit numbers.

The trial randomized 8,888 post-heart-attack patients to high-dose atorvastatin (80 mg) or usual-dose simvastatin (20-40 mg) [1]. The headline finding: atorvastatin cut nonfatal heart attacks by about 11% (321 vs 411 events) [1]. But look at the harms. Adverse effects forcing drug discontinuation hit 9.6% of atorvastatin patients versus 4.2% on simvastatin [1]. That is a number needed to harm of 43. The number needed to treat for one prevented nonfatal heart attack was 45 [1]. The drug harmed one person for roughly every person it helped, and that is before counting the 645 atorvastatin patients who stopped the drug versus 14 on simvastatin [1].

The trial's own numbers show the trade: for every 100 patients treated with high-dose atorvastatin instead of simvastatin, about 2 more had to quit due to side effects, while about 1 avoided a nonfatal heart attack [1]. The all-cause mortality difference was not significant [1]. This is not a safety signal from passive surveillance; it is a randomized controlled trial with hard clinical endpoints, and the harm rate still exceeded the benefit rate.

The evidence base for statins generally is built on industry-funded trials using surrogate LDL endpoints [2]. The IDEAL study at least measured real outcomes, and its own data shows the high-dose strategy trades real side effects for a marginal reduction in nonfatal events, with no mortality benefit [1]. Confidence: high that the published numbers are accurate. Confidence: high that the risk-benefit ratio for high-dose atorvastatin in secondary prevention is far less favorable than the "fire and forget" prescribing pattern suggests.